Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ALLOS THERAPEUTICS INC | a09-34965_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2009 (December 5, 2009)
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-29815 |
|
54-1655029 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
11080 CirclePoint Road, Suite 200 |
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 — Other Events
Item 8.01 Other Events.
On December 5, 2009, Allos Therapeutics, Inc. (the “Company”) issued a press release announcing new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYNTM (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The Company also reported preliminary results from its Phase 1/2 study of FOLOTYN in combination with gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies and certain other data presented during poster sessions at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
99.1 |
|
Press Release, dated December 5, 2009, entitled “Allos Therapeutics Reports New Analyses from Pivotal PROPEL Trial of FOLOTYNTM at 51st ASH Annual Meeting.” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: December 7, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
ALLOS THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Marc H. Graboyes |
|
|
|
Marc H. Graboyes |
|
|
Its: |
Senior Vice President, General Counsel and Secretary |
3
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release, dated December 5, 2009, entitled “Allos Therapeutics Reports New Analyses from Pivotal PROPEL Trial of FOLOTYNTM at 51st ASH Annual Meeting.” |
4